NASDAQ:RZLT Rezolute (RZLT) Stock Forecast, Price & News $1.37 +0.04 (+3.01%) (As of 12:32 PM ET) Add Compare Share Share Today's Range$1.33▼$1.4350-Day Range$1.33▼$2.0452-Week Range$1.30▼$2.97Volume35,066 shsAverage Volume30,408 shsMarket Capitalization$50.46 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Rezolute MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside529.4% Upside$9.00 Price TargetShort InterestBearish0.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 12 Articles This WeekInsider TradingAcquiring Shares$9,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.17) to ($1.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector344th out of 961 stocksPharmaceutical Preparations Industry147th out of 454 stocks 3.5 Analyst's Opinion Consensus RatingRezolute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Rezolute has a forecasted upside of 529.4% from its current price of $1.43.Amount of Analyst CoverageRezolute has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted0.94% of the outstanding shares of Rezolute have been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Rezolute has recently increased by 0.49%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRezolute does not currently pay a dividend.Dividend GrowthRezolute does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RZLT. Previous Next 2.6 News and Social Media Coverage News SentimentRezolute has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Rezolute this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.20% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.79% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Rezolute are expected to grow in the coming year, from ($1.17) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rezolute is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rezolute is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRezolute has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rezolute (NASDAQ:RZLT) StockRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More RZLT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RZLT Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comCantor Fitzgerald Comments on Rezolute, Inc.'s FY2024 Earnings (NASDAQ:RZLT)September 21, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Rezolute, Inc.'s Q1 2024 Earnings (NASDAQ:RZLT)September 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 20, 2023 | americanbankingnews.comRezolute (NASDAQ:RZLT) Given Overweight Rating at Cantor FitzgeraldSeptember 20, 2023 | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Expected to Earn Q1 2025 Earnings of ($0.30) Per ShareSeptember 19, 2023 | americanbankingnews.comRezolute's (RZLT) Buy Rating Reiterated at HC WainwrightSeptember 18, 2023 | markets.businessinsider.comExpert Ratings for RezoluteSeptember 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rezolute (RZLT), TG Therapeutics (TGTX) and Harpoon Therapeutics (HARP)September 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 17, 2023 | americanbankingnews.comRezolute's (RZLT) Market Outperform Rating Reiterated at JMP SecuritiesSeptember 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Iovance Biotherapeutics (IOVA)September 14, 2023 | finance.yahoo.comRezolute Reports Full Year Fiscal 2023 Results and Highlights Company ProgressAugust 22, 2023 | finance.yahoo.comWe Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth CarefullyJuly 6, 2023 | msn.comRezolute (RZLT) Price Target Decreased by 27.78% to 7.96June 29, 2023 | msn.comCantor Fitzgerald Maintains Rezolute (RZLT) Overweight RecommendationJune 29, 2023 | msn.comHC Wainwright & Co. Reiterates Rezolute (RZLT) Buy RecommendationJune 28, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About RezoluteJune 28, 2023 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on Rezolute (RZLT)June 27, 2023 | finance.yahoo.comRezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital HyperinsulinismJune 20, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on Rezolute (RZLT)May 22, 2023 | benzinga.comRezolute Stock (NASDAQ:RZLT), Insider Trading ActivityMay 15, 2023 | msn.comHC Wainwright & Co. Maintains Rezolute (RZLT) Buy RecommendationMay 12, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for Rezolute (RZLT)March 23, 2023 | finance.yahoo.comRezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular EdemaMarch 8, 2023 | finance.yahoo.comRezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical ExpertDecember 15, 2022 | finance.yahoo.comRezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular EdemaNovember 9, 2022 | finance.yahoo.comRezolute Reports First Quarter Fiscal 2023 Results and Highlights Company ProgressSee More Headlines Receive RZLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Email Address RZLT Company Calendar Last Earnings9/14/2023Today9/26/2023Next Earnings (Estimated)11/08/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RZLT CUSIPN/A CIK1509261 Webwww.rezolutebio.com Phone(650) 206-4507FaxN/AEmployees47Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+576.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.51% Return on Assets-36.72% Debt Debt-to-Equity RatioN/A Current Ratio20.17 Quick Ratio20.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book0.42Miscellaneous Outstanding Shares36,830,000Free Float30,125,000Market Cap$48.98 million OptionableNot Optionable Beta2.16 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Nevan Charles Elam J.D. (Age 56)Founder, CEO & Acting Chairman Comp: $918.34kDr. Brian Kenneth Roberts M.D. (Age 48)Chief Medical Officer Comp: $575.43kMr. Chris MilksVP & Head of Fin.Dr. Davelyn Eaves Hood M.B.A.M.D., Director and Head of Scientific & Patient AffairsMr. Michael R. DeperroSr. VP & Head of Corp. Devel.Mr. Michael CovarrubiasSr. VP & Head of Program & Portfolio ManagementDr. Raj Agrawal M.D.VP & Head of Ophthalmological Clinical Devel.Ms. Robyn SweinhartVP & Head of QualityMs. Erin O'BoyleSr. VP & Head of Clinical OperationsMs. Susan Stewart J.D. (Age 62)L.L.M., Chief Regulatory Officer More ExecutivesKey CompetitorsRockwell MedicalNASDAQ:RMTIHookipa PharmaNASDAQ:HOOKFSD PharmaNASDAQ:HUGEAEON BiopharmaNASDAQ:AEONImmix BiopharmaNASDAQ:IMMXView All CompetitorsInsiders & InstitutionsStonepine Capital Management LLCSold 15,173 shares on 8/16/2023Ownership: 8.342%Caxton CorpSold 84,190 shares on 8/15/2023Ownership: 3.581%Silverarc Capital Management LLCBought 499,544 shares on 8/15/2023Ownership: 1.356%Citadel Advisors LLCSold 12,999 shares on 8/15/2023Ownership: 0.890%Northern Trust CorpBought 11,219 shares on 8/11/2023Ownership: 0.234%View All Insider TransactionsView All Institutional Transactions RZLT Stock - Frequently Asked Questions Should I buy or sell Rezolute stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RZLT shares. View RZLT analyst ratings or view top-rated stocks. What is Rezolute's stock price forecast for 2023? 3 brokers have issued 12-month price targets for Rezolute's shares. Their RZLT share price forecasts range from $5.00 to $14.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 576.7% from the stock's current price. View analysts price targets for RZLT or view top-rated stocks among Wall Street analysts. How have RZLT shares performed in 2023? Rezolute's stock was trading at $2.07 at the beginning of 2023. Since then, RZLT shares have decreased by 35.7% and is now trading at $1.33. View the best growth stocks for 2023 here. When is Rezolute's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our RZLT earnings forecast. How were Rezolute's earnings last quarter? Rezolute, Inc. (NASDAQ:RZLT) announced its quarterly earnings data on Thursday, September, 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.11. What other stocks do shareholders of Rezolute own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rezolute investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Acasti Pharma (ACST), CymaBay Therapeutics (CBAY), Entasis Therapeutics (ETTX), Akero Therapeutics (AKRO), Cumberland Pharmaceuticals (CPIX), Evofem Biosciences (EVFM) and Evelo Biosciences (EVLO). What is Rezolute's stock symbol? Rezolute trades on the NASDAQ under the ticker symbol "RZLT." Who are Rezolute's major shareholders? Rezolute's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (8.34%), Stonepine Capital Management LLC (8.34%), Caxton Corp (3.58%), Silverarc Capital Management LLC (1.36%), Citadel Advisors LLC (0.89%) and Northern Trust Corp (0.23%). Insiders that own company stock include Brian Kenneth Roberts, Genexine Inc and Gil M Labrucherie. View institutional ownership trends. How do I buy shares of Rezolute? Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rezolute's stock price today? One share of RZLT stock can currently be purchased for approximately $1.33. How much money does Rezolute make? Rezolute (NASDAQ:RZLT) has a market capitalization of $48.98 million. The company earns $-51,790,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. How can I contact Rezolute? Rezolute's mailing address is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. The official website for the company is www.rezolutebio.com. The company can be reached via phone at (650) 206-4507 or via email at investor-relations@rezolutebio.com. This page (NASDAQ:RZLT) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.